HROW
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a massive premium to book value; Graham Number not applicable due to lack of positive earnings/book stability.
- Forward P/E of 13.21 is reasonable for the sector
- Price/Book of 25.50 is excessively high
- Price/Sales of 4.91 is steep
Growth is driven by sales expansion, but not yet translating to consistent bottom-line growth.
- Consistent 33% revenue growth
- Strong analyst price targets
- Earnings growth is trending negative (-10.3% YoY)
Historical price performance is strong, but earnings track record is erratic.
- Strong 5-year price trajectory
- Highly volatile quarterly earnings surprises
High leverage and low F-Score suggest significant structural financial risk.
- Current and Quick ratios indicate good short-term liquidity
- Piotroski F-Score of 2/9 indicates weak financial health
- Debt/Equity of 4.84 is dangerously high
Company is in a growth/reinvestment phase with 0/100 dividend strength.
- No dividend paid
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HROW and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HROW
Harrow, Inc.
Primary
|
+422.2% | +56.8% | +53.0% | -4.1% | -2.7% | +1.8% |
|
ATAI
AtaiBeckley Inc.
Peer
|
-81.0% | +212.7% | +165.5% | -20.3% | -7.0% | +8.8% |
|
HCSG
Healthcare Services Group, Inc.
Peer
|
-26.4% | +29.9% | +99.3% | +28.4% | -2.7% | +6.2% |
|
ARDX
Ardelyx, Inc.
Peer
|
-17.1% | +46.3% | +6.6% | -12.6% | -20.4% | -6.6% |
|
BCRX
BioCryst Pharmaceuticals, Inc.
Peer
|
-25.9% | -38.3% | -12.2% | -20.6% | -11.8% | +1.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HROW
Harrow, Inc.
|
NEUTRAL | $1.34B | - | -8.5% | -1.9% | $35.93 | |
|
ATAI
AtaiBeckley Inc.
|
BEARISH | $1.34B | - | -390.0% | -% | $3.69 | Compare |
|
HCSG
Healthcare Services Group, Inc.
|
BULLISH | $1.37B | 24.06 | 11.7% | 3.2% | $19.49 | Compare |
|
ARDX
Ardelyx, Inc.
|
NEUTRAL | $1.42B | - | -36.2% | -15.1% | $5.78 | Compare |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
NEUTRAL | $1.43B | - | -% | -1.5% | $6.79 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 198,572 | $7,846,426 |
| 2026-02-27 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 5,000 | $270,900 |
| 2026-01-06 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | 20,000 | $1,066,914 |
| 2025-12-12 | BAUM MARK L | Chief Executive Officer | Option Exercise | 180,000 | $711,000 |
| 2025-12-12 | BOLL ANDREW R | President | Option Exercise | 60,000 | $237,000 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning HROW from our newsroom.